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a  b  s  t  r  a  c  t
The  hepatitis  delta  virus  (HDV)  is  a  pathogen  that  causes  a  severe  and  rapidly  progressive  disease  of
hepatocytes.  The  measurement  of viral  load  in  the  peripheral  blood  of patients  with  HDV infections  is
important  for diagnosis,  treatment  monitoring,  and  support  for follow-up  studies  of  viral  replication  dur-
ing  the  course  of  the  disease.  This  study  reports  the  development  of an  assay  capable  of  detecting  and
quantifying  the abundance  of  HDV  particles  in  serum  samples,  based  on  reverse-transcription  quantita-
tive  PCR  (RT-qPCR).  Two  standards  for calibration  were  produced  for determining  the  viral  load  of HDV:
a  cDNA  cloned  into  a linear  plasmid  and  a transcribed  RNA.  For  validating  this assay,  140 clinical  samples
of  sera  were  used,  comprising  100  samples  from  patients  who  tested  positive  for anti-HDV  and  hepatitis
B virus  surface  antigen  (HBsAg)  by ELISA;  30 samples  from  blood  donors;  5  samples  monoinfected  withuantitative real-time PCR
ydrolysis probe
iral load
hepatitis  B virus  (HBV);  and  5  samples  monoinfected  with  hepatitis  C virus  (HCV).  The  HDV RT-qPCR  assay
performed  better  when  calibrated  using  the standard  based  on  HDV  cDNA  cloned  into  a linear  plasmid,
yielding  an  efﬁciency  of  99.8%  and  a speciﬁcity  of  100%  in the in vitro  assays.  This  study  represents  the
ﬁrst  HDV  RT-qPCR  assay  developed  with  clinical  samples  from  Brazil  and  offers  great potential  for  new
clinical  efﬁcacy  studies  of  antiviral  therapeutics  for use in patients  with  hepatitis  delta  in  the  western
Amazon  region.. Introduction
Hepatitis delta, which is also known as hepatitis D, is an infec-
ious viral illness that causes grave inﬂammation of hepatocytes
Saracco et al., 1987; Le Gal et al., 2005; Farci and Niro, 2012). Sev-
ral studies have shown that chronic infection with hepatitis delta
irus (HDV) leads to more severe liver disease than monoinfection
ith chronic hepatitis B virus (HBV), with accelerated progression
o ﬁbrosis, cirrhosis, and decompensation of early increased risk
f hepatocellular carcinoma (Bensabath et al., 1987; Romeo et al.,
Abbreviations: HDV, hepatitis delta virus; HBV, hepatitis B virus; RT-qPCR,
everse-transcription quantitative PCR; HBsAg, hepatitis B virus surface antigen.
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2009; Niro et al., 2010; Wedemeyer, 2011; Buti et al., 2011). HDV
infection can therefore occur as either a superinfection or a coin-
fection. Coinfection is simultaneous infection with both HBV and
HDV; it is clinically indistinguishable from acute monoinfection
caused by HBV, although it may  be more serious. Superinfection
is HDV infection in an individual who  is chronically infected with
HBV (Smedile et al., 1982). Occasionally, HDV superinfection can
be self-limiting. In this case, HDV RNA is eliminated in a few years.
Antiviral therapy can also hasten HDV RNA elimination, and in some
cases, the antibodies against HDV and hepatitis B virus surface
antigen (HBsAg) disappear from the sera. In HDV  superinfection
with persistent viral replication, commonly observed levels of HDV
RNA, alamine aminotransferase, and elevated antibodies to HDV
are persistently detectable (Hughes et al., 2011). The HDV  is a
small, spherical particle that is encapsulated by an HBsAg enve-
lope that measures approximately 36 nm.  HDV is considered to
be a satellite virus of HBV (Bonino et al., 1986). The virion con-
tains a single-strand negative-sense RNA genome of approximately
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700 nt that is circular and self-complementary (Taylor, 2006;
ughes et al., 2011). Its genetic diversity is related to the geo-
raphical origin of the isolate. Thus far, 8 genotypes have been
dentiﬁed and classiﬁed as HDV-1 to HDV-8 (Le Gal et al., 2006).
DV-3 is responsible for epidemics of severe hepatitis and is com-
on in northeastern South America (Casey et al., 1993a,b). Studies
how that HDV-3 is prevalent in the Brazilian Amazon (Gomes-
ouvea et al., 2009; Alvarado-Mora et al., 2011). This HDV genotype
s apparently related to the greater aggressiveness of HDV in this
egion (Casey et al., 1993b; Viana et al., 2005; Parana et al., 2006).
Molecular studies based on the quantitation of HDV RNA
hrough real-time reverse transcription polymerase chain reac-
ion (RT-qPCR) with a Light Cycler DNA Master SYBR Green I
ix  (Boehringer Mannheim, Mannheim, Germany) demonstrated
 correlation between levels of RNA HDV circulating in sera and
iver damage. In addition, HBV DNA levels showed no correla-
ion among the different clinical stages (Yamashiro et al., 2004).
uantitation of HDV RNA in sera is critical for diagnosing infection
nd monitoring treatment, because it allows for the identiﬁca-
ion of proﬁles of different viral responses to interferon therapy
ith greater precision than qualitative tests (Le Gal et al., 2005;
ederacke et al., 2010). In 2009, Kiesslich and colleagues per-
ormed real-time RT-qPCR analysis to assess the inﬂuence of
he HBV genotype on the disease course in HBV–HDV-coinfected
atients by measuring their viral loads. In 2012, Ferns and col-
aborators developed a standardized RT-qPCR assay in real time
y using a transcript of “full-length genomic RNA” in order to
inimize the risk of producing false-negative results and under-
stimating the viral load. Shang et al. (2012) developed a real-time
T-qPCR assay to determine the viral load using sera or plasma
nfected with all HDV types. Many studies have used in-house RT-
PCR assays for monitoring treatments (Yamashiro et al., 2004; Le
al et al., 2005; Castelnau et al., 2006; Farci, 2006); thus, many
aboratories have developed real-time RT-qPCR assays in-house
n order to diagnose and monitor the treatment of HDV infec-
ion because there is no commercial test yet available. Currently
vailable methods for serological diagnosis of hepatitis delta have
ower speciﬁcity than other clinical methods. The method pro-
osed here for molecular HDV RT-qPCR is meant to fulﬁll the
eed to increase the clinical speciﬁcity of diagnosis and treat-
ent monitoring of hepatitis delta in the Amazon region of Brazil.
owever, this proposed method is limited by the lack of an inter-
ational standard to regulate assays for quantiﬁcation of HDV
NA. The aim of this study was to produce an in-house RT-qPCR
est to enable the early diagnosis and quantiﬁcation of HDV for
reatment monitoring, given that the western Amazon region of
razil is considered to be an area of high endemicity for this
irus.
. Methods
.1. Clinical samples
The study included 100 serum samples from patients found
o be infected with HBV/HDV following outpatient service in
iral hepatitis at the Research Center for Tropical Medicine
rom Rondônia, Porto Velho, Brazil. To test speciﬁcity, a con-
rol group of 30 blood donors was included, all of whom
ere negative for human immunodeﬁciency virus (HIV)-1 and
IV2, HBsAg, anti-HBc, and anti-hepatitis C virus (HCV). We
lso tested 5 serum samples from individuals monoinfected
ith HCV and 5 samples from individuals who  were HBV
onoinfected. This study was approved by the ethics com-
ittee of the Research Center for Tropical Medicine (approval
3/10 CEP/Research Center Tropical Medicine and Registration No.
10/2010).logical Methods 197 (2014) 19– 24
2.2. HDV RNA extraction
HDV RNA extraction was  performed with the QIAamp Viral
RNA Mini Kit (Qiagen, Germany) using 200 L sera, according
to the manufacturer’s instructions. The RNA precipitate was re-
suspended in 50 L of elution buffer. To prevent false-positive
results, strict procedures and proposed techniques for nucleic acid
ampliﬁcation diagnostics were followed (Kwok and Higuchi, 1989).
2.3. Reverse transcription
HDV RNA was denatured at 95 ◦C for 5 min  and 15 L of the RNA
extraction was  converted into cDNA using 200 U of M-MLV enzyme
(Sigma–Aldrich®, Saint Louis, USA), 1 L of 10× M-MLV  reverse
transcriptase buffer, 1 L of random primer, and 1 L of 10 mM
dNTP mix. The thermocycling conditions for cDNA synthesis were
as follows: 70 ◦C for 10 min, 37 ◦C for 50 min, and 94 ◦C for 10 min.
2.4. Design and optimization of primers and ﬂuorescence
resonance energy transfer probes
The primers and hydrolysis probe (TaqMan Probes, Applied
Biosystems, Foster City, CA, USA) were designed based on known
and complete HDV sequences that are deposited in GenBank
and were obtained from the National Center for Biotechnology
Information (NCBI) using CLUSTAL W 2.1 software (European Bioin-
formatics Institute). Nucleotide sequences of the 8 genotypes that
are described in the database were aligned and mapped in terms
of their conserved regions. To analyze the in silico speciﬁcity of the
primers, we used the Basic Local Alignment Search Tool (BLAST) at
the NCBI. Primer concentration was optimized using a concentra-
tion gradient from 100 nM to 900 nM.  Optimization of the probe
concentration was conducted using a concentration gradient from
50 nM to 300 nM using the TaqMan® PCR Master Mix  (Applied
Biosystems, Foster City, CA, USA).
2.5. HDV-qPCR
HDV-qPCR was  performed on the ABI 7500 platform (Applied
Biosystems, Foster City, CA, USA) with a 25-L reaction volume con-
taining 12.5 L TaqMan Universal Master Mix 2× (Applied Biosys-
tems, Foster City, CA, USA), 5 L of cDNA, 100 nM of the forward
primer HDVq (nt) 5′-TGGCTCTCCCTTAGCCATCCGA-3′, 100 nM
primer Reverse HDVqb (nt) 5′-GGGTTTCCACTCACAGGTTTGC-3′,
and 100 nM of the probe 5′-FAM-CCGCGAGGAGGTGGAGATGCCAT-
TAMRA-3′, which amplify a fragment of approximately 135 nt
production corresponding to HDAg-L.
2.6. Generation of a standard curve
2.6.1. RT-PCR
For of standardized controls, HDV RNA was  extracted and
reverse transcribed (as described in Sections 2.2 and 2.3); we used
a sample of serum found to be positive for anti-HgsAg and HDV,
as determined by ELISA (DiaSorin, Saluggia, VC, Italy). For the RT-
PCR, we used 10 L of extracted RNA and added it to 40 L of PCR
mix  (20 mM Tris–HCl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
each of the 4 dNTPs, 10 pmol of each primer, and 1.25 U of Taq DNA
polymerase [InvitrogenTM Life Technologies, Carlsbad, CA, USA]).
PCR was performed under the following conditions: 2 min at 94 ◦C
followed by 40 cycles of 30 s at 94 ◦C, 50 s at 60 ◦C, and 45 s at 72 ◦C,
with a ﬁnal extension step of 5 min  at 72 ◦C.
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Fig. 1. Multiple alignment using CLUSTAL W 2.1 for HDV RNA sequences that were drawn from GenBank and corresponded to 8 genotypes (HDV-1 through HDV-8). The
f ted a s
a X8525
A 18333
2
i
(
c
n
i
(
(
e
g
c
i
i
w
1
e
t
H
2
g
t
N
m
w
t
e
g
l
t
2
2
e
i
(
2
t
(
Eorward primer demonstrated a score from 90 to 100, the reverse primer demonstra
ligned sequences of HDV RNA (GenBank IDs: U81988, M84917, AF104263, D01075, 
B037947, AB037948, AF209859, AF018077, AX741154, AX741159, AX741149, AM
.6.2. Cloning of cDNA into plasmids and RNA transcription
n vitro
The PCR product was puriﬁed using an ExoSAP-IT® enzyme
USB, Cleveland, OH, USA) and the fragment was inserted into a
loning plasmid pTZ57R/T (Fermentas®, Hanover, MD,  USA) con-
ected with T4 DNA Ligase (Promega, Madison, USA), and cloned
nto a prokaryotic system. The cloned cDNA was digested with EcoRI
InvitrogenTM Life Technologies, Carlsbad, CA, USA) and BamHI
InvitrogenTM Life Technologies, Carlsbad, CA, USA) and the pres-
nce of the insert was conﬁrmed by electrophoresis on an agarose
el, followed by subsequent linearization with EcoRI, resulting in
alibration standard HDV cDNA. Thereafter, 10 L of cDNA was
nserted into the linearized plasmid, which was  then transcribed
n vitro by using T7 RNA polymerase (Promega®, Madison, WI,  USA)
ith a 100 L reaction volume containing transcription-optimized
× buffer, 100 mM DTT, ribonuclease inhibitor 40 U/L, 2 nM of
ach of the 4 rNTPs, and 19 U/L phage RNA polymerase. The mix-
ure was incubated at 37 ◦C for 2 h to obtain calibration standard
DV RNA.
.6.3. Quantitation and control of calibrators
The integrity calibrators were conﬁrmed by performing agarose
el electrophoresis. The concentration was measured spectropho-
ometrically using a NanoDrop® ND-1000 (Thermo Scientiﬁc
anoDrop Products, Wilmington, Delaware), and the measure-
ents were recorded in units of nanograms per microliter, which
as converted into copies per microliter using the following equa-
ion: ([× ng/L × 10−9]/[DNA bps × 660]) × 6.022e23 = y copies/L
([× ng/L × 10−9]/[RNA bps × 350]) × 6.022e23 = y copies/L (Qia-
en, West Sussex, UK). Both solutions were diluted to obtain the
inear dynamic range of the calibrators. Subsequently, the calibra-
ion dilutions of standard RNA were converted into cDNA.
.7. Analytical performance
.7.1. Analytical sensitivity and linear dynamic range
The limit of detection and the linear dynamic range were
stablished by linear regression production of HDV-qPCR assays
n vitro, using 3 repetitions of a serial dilution of 6-log10
102–107 copies/reaction) of both standard controls (Bustin, 2010).
.7.2. Analytical speciﬁcity
To demonstrate the analytical speciﬁcity of HDV RT-qPCR, we
ested 100 serum samples from patients infected with HDV/HBV
HBsAg, anti-HBc, which were found to be anti-HDV positive by
LISA). We  also used 30 samples from blood donors, 5 serumcore from 77 to 95, and the probe demonstrated a score from 95 to 100 between the
3, AY633627, AB088679, AF30942, AF104264, U19598, X60193, L22063, AB037949,
1, AM183326, AM183328, AM183329, AJ584847, AM183333, and AM183327).
samples from patients chronically infected with HCV, and 5 serum
samples from HBV monoinfected patients. All samples were sub-
jected to HDV-qPCR to determine their viral load.
2.7.3. Ampliﬁcation efﬁciency and linearity of HDV-qPCR
The linearity of HDV-qPCR was evaluated by means of 4 rounds
of a serial dilution of 6-log10 of both standard controls (Bustin,
2010). The efﬁciency was  calculated using the equation: Ampli-
ﬁcation Efﬁciency = [10(−1/slope) − 1] × 100 (Le Gal et al., 2005).
2.7.4. Reproducibility and repeatability
Intra-assay reproducibility was evaluated by means of 4 rounds
of a serial dilution of 6-log10 of both standard controls. To evalu-
ate inter-assay repeatability, we  performed the assay with 6 sera
samples in 4 rounds on consecutive days (Bustin, 2010).
2.8. Statistical analysis
Statistical analyses of both standard controls were performed
using GraphPad Prism 5.0 (GraphPad Software, CA, USA). The non-
parametric data were compared using the Mann–Whitney 2-tailed
U-test, and a p-value of <0.05 was  considered statistically signiﬁ-
cant.
3. Results
3.1. In silico analysis of primers and FRET probes
In silico analysis of the primers and FRET probes demonstrated
that these were highly speciﬁc for the HDV genome. The primers
and FRET probes were capable of binding to the conserved regions
among the 8 presently known genotypes of HDV RNA with high
speciﬁcity (Fig. 1).
3.2. Analytical performance
3.2.1. Analytical sensitivity and linear dynamic range
The linear dynamic ranges that were successfully
tested for HDV-qPCR were 1.3 × 102–1.3 × 107 and
8.4 × 101–8.4 × 106 copies/mL for the calibration standard HDV
cDNA and RNA, respectively (Figs. 2 and 3). The limits of detection
were 1.3 × 102 and 8.4 × 101 copies/mL for the calibration standard
HDV cDNA and RNA, respectively (Figs. 2 and 3).
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Fig. 2. Linear regression curve of the calibrator standard HDV cDNA. The linear
regression curve was shown to be signiﬁcant (p ≤ 0.0001) with a slope of −3.325,
linear correlation coefﬁcient R2 = 0.96, generated using the following formula to
determine the viral load: y = −3.325x + 40.12.
Fig. 3. Linear regression curve of the calibrator standard HDV RNA. The linear regres-
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Table 1
Intra-run repeatability of HDV cDNA standards evaluated with 3 replicates of 6-fold
standard dilutions.
cDNA (copies/mL) 1st run
(Ct)
2nd
run (Ct)
3rd run
(Ct)
Mean SD(±) CV (%)
1.3 × 107 14.95 15.71 16.16 15.61 0.61 0.04
1.3  × 106 18.92 19.81 20.32 19.68 0.71 0.04
1.3  × 105 22.92 24.35 25.12 24.13 1.12 0.05
1.3  × 104 26.55 27.09 27.47 27.04 0.46 0.02
1.3  × 103 30.07 30.60 30.82 30.50 0.38 0.01
1.3  × 102 31.52 32.04 31.87 31.81 0.27 0.01
Slope −3.427 −3.336 −3.211 −3.325 0.07
Intercept 39.95 40.31 40.10 40.12 0.27
Correlation
coefﬁcient (R2)
0.98 0.97 0.96 0.97
Table 2
Intra-run repeatability of HDV cDNA standards evaluated with 3 replicates of 6-fold
standard dilutions.
cDNA (copies/mL) 1st run
(Ct)
2nd
run (Ct)
3rd run
(Ct)
Mean SD(±) CV (%)
8.4 × 106 22.09 22.10 22.07 22.09 0.02 0.00
8.4  × 105 25.76 25.51 26.00 25.76 0.25 0.01
8.4  × 104 28.29 28.19 28.38 28.29 0.10 0.00
8.4  × 103 31.57 31.50 31.63 31.57 0.07 0.00
8.4  × 102 33.95 33.83 34.07 33.95 0.12 0.00
8.4  × 101 37.00 37.35 36.65 37.00 0.35 0.01
Slope −3.146 −29.860 −2.867 −29.260 0.14
Intercept 41.66 42.95 42.47 42.36 0.65
Correlation 0.99 0.99 0.99 0.99
F
q
s
lion  curve was shown to be signiﬁcant (p ≤ 0.0001) with a slope of −2.926, linear
orrelation coefﬁcient R2 = 0.99, generated using the following formula to determine
he  viral load: y = −2.926x + 42.71.
.2.2. Analytical speciﬁcity in vitro
Of 100 sera samples of HBsAg- and anti-HDV-positive patientsho were tested by performing HDV-qPCR, 54% were positive, with
 viral load greater than or equal to the detection limit and 46% were
onsidered to be negative because they were below the detection
imit of the assay, as determined by the standard calibration HDV
ig. 4. Viral load (log10 copies/mL) of serum HBsAg- and anti-HDV-positive samples as d
PCR  assay (2.11 log10 or 1.3 × 102 copies/mL). At the left side of the dashed line are the 4
tandard HDV cDNA, and to the right side of the dashed line are the 54% of the samples th
imit  of the HDV-qPCR assay. The viral load of the samples was determined using the equcoefﬁcient (R2)
cDNA (Fig. 4). All 30 sera samples from the blood donors, the 5
sera samples from the patients chronically infected with HCV, and
the 5 sera samples from the patients monoinfected with HBV were
negative.
3.2.3. Ampliﬁcation efﬁciency and linearity of HDV-qPCR
The linearity of HDV-qPCR was evaluated by constructing a
linear regression curve for each run of serial dilutions of 6-log10
calibration standard HDV cDNA and RNA, and we found a strong
correlation between the dilutions (correlation coefﬁcient R2 = 0.97
and 0.99) for both standards (Tables 1 and 2). The ampliﬁcation
efﬁciency was  calculated from the slope, and was −3325 (99.8%)
and −2.92 (119%) for calibration standard HDV cDNA and RNA,
respectively.
etermined from ELISA. The dashed line represents the detection limit of the HDV-
6% of the samples that were considered negative as determined from the calibrator
at were considered positive with viral loads greater than or equal to the detection
ation presented in Fig. 2.
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Table 3
Inter-run reproducibility of HDV cDNA standards evaluated with 3 replicates of 6 samples.
Sample 1st run (copies/mL) 2nd run (copies/mL) 3rd run (copies/mL) Mean SD(±) CV (%)
1 9.1 × 102 8.3 × 102 8.1 × 102 8.5 × 102 5.3 × 101 0.06
2  1.3 × 103 1.2 × 103 1.2 × 103 1.2 × 103 6.2 × 101 0.05
3  8.6 × 102 7.6 × 102 5.9 × 102 7.4 × 102 1.3 × 102 0.18
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d4  2.5 × 10 2 × 10
5  1.3 × 102 1.5 × 102
6  1.9 × 103 1.7 × 103
.2.4. Reproducibility and repeatability
Repeatability was measured by determining the intra-assay
tandard deviation (SD), where the SD varied from 0.27 to 0.71
nd from 0.02 to 0.35 for calibration standard HDV cDNA and RNA,
espectively (Tables 1 and 2). Reproducibility of the HDV-qPCR
ssay was conﬁrmed by inter-assay analyses, where the HDV RNA
as quantiﬁed in sera samples using 6 × 3 runs on consecutive days
Table 3). The HDV-qPCR assay is highly capable of determining
he viral load (using the equation shown in Fig. 2) of sera samples
ith low variability between runs. Tests showed that the SD was
.1 × 101–2.8 × 102 copies/mL and that the coefﬁcient of variation
CV) was 0.05–0.18.
. Discussion
The high genetic diversity of HDV has been problematic for
he standardization of in-house real-time PCR assays, especially
hen using probe-based techniques, because HDV’s small genome
ombined with its high genetic diversity hamper design of HDV
ydrolysis probes that bind efﬁciently to all viral genotypes
Yamashiro et al., 2004; Shang et al., 2012). In this study, we
esigned primers and hydrolyzable probes that are capable of
etecting all genotypes (Fig. 1) without the need for additional
rimers as described in other studies (Le Gal et al., 2005; Schaper
t al., 2010). The primers aligned with HDV RNA sequences of all
enotypes, and the isolates that are deposited in GenBank scored
0–100, 95–97, and 95–100 for the forward primer, probe, and
everse primer, respectively, which corresponded to optimal speci-
city in silico. Analytical speciﬁcity was conﬁrmed with in vitro tests
here blood samples from HBV-negative, HCV-monoinfected indi-
iduals were subjected to RT-qPCR HDV, thereby demonstrating
hat the test did not produce false-positive results (in vitro speci-
city = 100%).
Le Gal et al. (2005) used a speciﬁcity assay with 26 negative
ontrol samples, of which 5 were positive for HBsAg and HBV DNA,
 were positive for HCV RNA, reagents 04 anti-HAV-IgM 05 HIV-
NA 01–05 HEV-RNA and negative for HBV, HCV, HAV, HEV, and
IV. Other studies have also used samples containing viruses other
han HDV to assay speciﬁcity, and have reported in vitro speciﬁcity
f 100% using negative control samples; these results are corrobo-
ated by the present study (Kiesslich et al., 2009; Mederacke et al.,
010; Ferns et al., 2012; Shang et al., 2012).
Of the 100 clinical samples that were HBsAg- and anti-HDV posi-
ive in the study, 54% were positive as determined using HDV-qPCR.
erological diagnosis of HDV infection is complex due to the natu-
al history of the infection itself. It is important to consider that the
erological ELISA that is used in the routine evaluation of patients
etects IgM or IgG antibodies and may  not reﬂect the presence of
iral RNA in the sera of these individuals, since we know that each
atient can be at a different stage of infection (Jardi et al., 1994;
edemeyer, 2011). A study by Jardi et al. (1994) demonstrated
hat sera anti-HDV IgM is the least speciﬁc marker for HDV chronic
nfection that is diagnosed by the detection of intra hepatic HDAg
r HDV RNA. In the present study, we developed a method that can
e used to detect HDV in patient sera directly, because it is based on
etection of HDV RNA, which may  explain why 46% of the samples2.5 × 10 2.3 × 10 2.9 × 10 0.13
1.3 × 102 1.3 × 102 1.1 × 101 0.08
1.3 × 103 1.6 × 103 2.8 × 102 0.17
were negative for the presence of RNA HDV  when screened with
anti-HDV reagent (Le Gal et al., 2005). These patients may  have had
super-infection with viral clearance via their immune response or
been HDV patients with viral loads below the limit of detection.
Regardless, the test offers guidelines to exclude antiviral therapy
in this group of patients. Currently, routine laboratory diagnosis
of HDV is accomplished by serologic methods. However, in recent
years molecular methods for nucleic acid ampliﬁcation-based tech-
niques in-house for real-time qPCR has been shown to diagnose a
variety of diseases with greater speciﬁcity.
The detection limit and linear dynamic range of our test
(1.3 × 102–1.3 × 107 and 8.4 × 101–8.4 × 106 copies/mL) proved to
be capable of detecting up to 130 and 84 copies/mL of standard HDV
cDNA and pattern RNA, respectively. The correlation coefﬁcients
(Pearson) of our RT-qPCR were R2 = 0.97 and 0.99, demonstrating
excellent linearity of the linear regression curves that were pro-
duced. The efﬁciency of the HDV RT-qPCR assay using HDV standard
cDNA was greater (average of 99.8% and slope −3.325) than that
using HDV standard RNA (average of 119% and slope −2.926); this
result may  be explained by the natural instability of RNA.
The intra-assay repeatability test showed that the HDV-qPCR
assay developed in this study is accurate and reliable (0.38 and
0.35 ± SD) for both standards (Tables 1 and 2), and that the inter-
assay reproducibility (CV% 0.18–0.05) showed low variation in
terms of quantifying the viral load in sera samples (Table 3). Sev-
eral in-house RT-qPCR HDV assays have been developed with
linear dynamic ranges, detection limits, efﬁciency FRET probes,
and primers; the use of different standards has resulted in the
absence of an international consensus for quantitation of viral load
(Yamashiro et al., 2004; Le Gal et al., 2005; Kiesslich et al., 2009;
Mederacke et al., 2010; Schaper et al., 2010; Ferns et al., 2012; Shang
et al., 2012).
We have developed an HDV-qPCR assay that can be used to
quantify HDV RNA in sera of patients with HDV that will serve
as tool for rapid, accurate, and reliable diagnosis in the western
Amazon region of Brazil.
5. Conclusions
These results open up possibilities for new clinical studies of
the efﬁcacy of anti-viral therapies used on patients with hepatitis
delta. They will also improve our understanding of the viral kinetics
of HBV and allow determination of how these viruses interact at
different time points throughout the infection, especially during
treatment.
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